PDE4A and Alzheimer disease: With a further understanding of the action of PDE4 and its isoforms in the CNS and advances in drug development technology, we are expected to develop more selective and effective PDE4 isoform-specific inhibitors for the treatment of neuropsychiatric disorders associated with AD.